evaluate the pharmaceuticals company zepbound on glp-1 and insurance providers Compare Options | Ozempic v Mounjaro | WeightWatchers 💉 Leading The GLP-1 Revolution

Data from that analysis (i.e., Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials) found a 266% increase in the risk of DVT for people taking semaglutide drugs

Elevated IGF-1 beyond the upper physiological range raises concerns about downstream effects, including fluid retention, carpal tunnel syndrome, and theoretical long-term risks requiring further evaluation

It failed to gain approval for obesity treatment following Phase II clinical trials in the mid-2000s, and no regulatory body has since approved it for any human indication

Here are the most common problems and their solutions